CGON as reported
CG Oncology, Inc. reported $6.2M of revenue over the trailing twelve months, +1030% on the year before. 9 reported series are charted on this page, each one as filed.
$6.2M
Revenue, trailing twelve months · to Q2 2026 · +1030% against the twelve months before
- Net Income
- −$224M
Net Income · +75% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$179M
Free Cash Flow · +91% year on year · trailing twelve months to Q2 2026
- Op Margin
- −4691%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $6.2M | +1030% | Q2 2026 |
| Net Income | −$224M | +75% | Q2 2026 |
| EPS | −$2.69 | +52% | Q2 2026 |
| Op Margin | −4691% | n/a | Q2 2026 |
| Net Margin | −4200% | n/a | Q2 2026 |
| ROE | −21% | n/a | Q2 2026 |
| ROA | −20% | n/a | Q2 2026 |
| ROIC | −2151% | n/a | Q2 2026 |
| Free Cash Flow | −$179M | +91% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
CG Oncology, Inc. (CGON) - Revenue & ProfitRevenue & ProfitCG Oncology, Inc. (CGON)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com